157 related articles for article (PubMed ID: 29605234)
1. [Biological and biosimilar drugs: Clarifying concepts].
Rodriguez Cumplido D; Asensio Ostos C
Aten Primaria; 2018; 50(6):323-324. PubMed ID: 29605234
[No Abstract] [Full Text] [Related]
2. Biosimilars versus biologics for inflammatory conditions.
Perry D; Ton J; Kolber MR
Can Fam Physician; 2019 Sep; 65(9):636. PubMed ID: 31515313
[No Abstract] [Full Text] [Related]
3. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
4. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
5. Biosimilars and drug development in allergic and immunologic diseases.
Bonini S; Bonini M
J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
[No Abstract] [Full Text] [Related]
6. [Biologics and biosimilars].
Guðmundsson K
Laeknabladid; 2014 May; 100(5):267. PubMed ID: 24846948
[No Abstract] [Full Text] [Related]
7. Forum discusses biosimilars, better biologicals.
Thompson CA
Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804
[No Abstract] [Full Text] [Related]
8. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
Mak JW; Sung JJ
J Gastroenterol Hepatol; 2019 Aug; 34(8):1269-1270. PubMed ID: 31456235
[No Abstract] [Full Text] [Related]
9. Biologicals and biosimilars: safety issues in Europe.
Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
[TBL] [Abstract][Full Text] [Related]
10. Similar and mimics: Latin America biosimilar regulations.
Lizarraga A; Mysler E
Int J Rheum Dis; 2019 Jan; 22(1):6-8. PubMed ID: 30689310
[No Abstract] [Full Text] [Related]
11. Biologicals and how they revolutionized rheumatology.
Grisar J
Wien Med Wochenschr; 2015 Jan; 165(1-2):1-2. PubMed ID: 25676698
[No Abstract] [Full Text] [Related]
12. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars.
Ross A; Richard K
Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
[No Abstract] [Full Text] [Related]
14. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
[TBL] [Abstract][Full Text] [Related]
16. A review of the United States' naming convention for biological products.
Saunders J; Proctor C; Shermock KM
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):750-753. PubMed ID: 32319139
[No Abstract] [Full Text] [Related]
17. The impact of specialty pharmaceuticals as drivers of health care costs.
Hirsch BR; Balu S; Schulman KA
Health Aff (Millwood); 2014 Oct; 33(10):1714-20. PubMed ID: 25288414
[TBL] [Abstract][Full Text] [Related]
18. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
20. Is it time for biosimilars in autoimmune diseases?
Cuadrado MJ; Sciascia S; Bosch X; Khamashta MA; Ramos-Casals M
Autoimmun Rev; 2013 Aug; 12(10):954-7. PubMed ID: 23542505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
